tbuckley/cabot-search huggingface dataset:
Problematic Strength of the Association Between Atopic Dermatitis and Suicidality
Authors: Hong-Lin Chen, Yi-Ping Song, Kun Liu
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Sixty seconds on . . . bad diets
Authors: Susan Mayor
Journal: BMJ (2019)

Apparently. According to last week’s newspaper headlines, unhealthy diets are responsible for one in five deaths around the world, more even than tobacco. They were reporting results from the Global Burden of Disease Study, published in the Lancet ,1 showing that “suboptimal” diets were responsible for around 11 million deaths in 2017. High intake of sodium and low consumption of whole grains and fruit were the main …
Diffuse-Type Tenosynovial Giant Cell Tumor of the Thoracic Spine
Authors: Guohua Shen, Huan Ma, Lili Pan, Minggang Su, Anren Kuang
Journal: Clinical Nuclear Medicine (2019)

Abstract D-TGCT (diffuse-type tenosynovial giant cell tumor) is a benign proliferative disorder of the synovial membranes that usually occurs in the appendicular skeleton, especially large joints such as the knee, hip, and elbow. It rarely involves the spine. In this report, we describe a rare case of D-TGCT in the thoracic spine, which showed a lytic lesion with high FDG uptake. It can mimic metastases or neurogenic tumors and should be included in the differential diagnosis of spinal tumors.
一种利用发光纤维进行 AK PDT 的新方案
Authors: C. Vicentini, A.S. Vignion‐Dewalle, E. Thecua, F. Lecomte, C. Maire, P. Deleporte, H. Béhal, D. Kerob, A. Duhamel, S. Mordon, L. Mortier
Journal: British Journal of Dermatology (2019)

日光性角化病 (AK) 是指主要在身体曝光部位(尤其是手和前臂背侧、面部和耳部以及光头男性头皮)发现的晒伤皮肤区域。它们通常是无害的,但可能不美观或带来不便,一些日光性角化病有进展成为鳞状细胞癌(一种皮肤癌)的极轻微风险。有若干可能的治疗,包括光动力疗法 (PDT),在此方法中,首先在受影响的皮肤区域涂敷称为光敏剂的乳膏,然后使用一种特殊光线将其激活。此疗法可杀灭皮肤中的异常细胞。欧洲批准用于 AK PDT 的光敏剂需要在施用光敏剂后 3 小时通过红光激活(称为 C‐PDT)或在施用光敏剂后 30 分钟内通过日光激活(称为 D‐PDT)。C‐PDT 的主要不足是治疗中疼痛,而 D‐PDT 由于施用光敏剂和日光激活的间隔时间短,因此几乎无痛。遗憾的是,D‐PDT 需要良好的气候条件。因此,来自法国 ONCO‐THAI 研究中心的这项研究的作者检测了在用药后 30 分钟使用一部柔韧发光纤维装置(此后称为 FLEXI‐PDT)通过红光激活光敏剂的方法。这项研究旨在评估 FLEXI‐PDT 在消除 AK 方面是否至少与 C‐PDT 一样有效。作者们还想知道 FLEXI‐PDT 和 C‐PDT 之间疼痛评分是否有差异。为此,35 名头皮 AK 患者使用 FLEXI‐PDT 治疗一侧头皮,用 C‐PDT 治疗另一侧头皮。患者分别在 FLEXI‐PDT 和 C‐PDT 期间评定他们的疼痛。由一名皮肤科医生在治疗后 3 个月评估各 AK 的缓解情况(完全或不完全消失)。通过对采集数据进行分析,作者们显示,可以在所有气候条件下实施的 FLEXI‐PDT 在消除 AK 方面至少与 C‐PDT 一样有效,且疼痛更轻。
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
Authors: Gayathri Anandappa, Andrea Lampis, David Cunningham, Khurum H. Khan, Kyriakos Kouvelakis, Georgios Vlachogiannis, Somaieh Hedayat, Nina Tunariu, Sheela Rao, David Watkins, Naureen Starling, Chiara Braconi, Mahnaz Darvish-Damavandi, Hazel Lote, Janet Thomas, Clare Peckitt, Ria Kalaitzaki, Nasir Khan, Nicos Fotiadis, Massimo Rugge, Ruwaida Begum, Isma Rana, Annette Bryant, Jens C. Hahne, Ian Chau, Matteo Fassan, Nicola Valeri
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from the anti-EGFR mAb cetuximab. Here, we aimed to validate the predictive power of miR-31-3p in a prospective cohort of chemorefractory mCRC patients treated with single-agent anti-EGFR mAbs. Experimental Design: miR-31-3p was tested by in situ hybridization (ISH) in 91 pretreatment core biopsies from metastatic deposits of 45 patients with mCRC. Sequential tissue biopsies obtained before treatment, at the time of partial response, and at disease progression were tested to monitor changes in miR-31-3p expression overtreatment. miR-31-3p expression, sidedness, and RAS status in pretreatment cell-free DNA were combined in multivariable regression models to assess the predictive value of each variable alone or in combination. Results: Patients with low miR-31-3p expression in pretreatment biopsies showed better overall response rate, as well as better progression-free survival and overall survival, compared to those with high miR-31-3p expression. The prognostic effect of miR-31-3p was independent from age, gender, and sidedness. No significant changes in the expression of miR-31-3p were observed when sequential tissue biopsies were tested in long-term or poor responders to anti-EGFR mAbs. miR-31-3p scores were similar when pretreatment biopsies were compared with treatment-naïve archival tissues (often primary colorectal cancer). Conclusions: Our study validates the role of miR-31-3p as potential predictive biomarker of selection for anti-EGFR mAbs.
AV Nodal Wenckebach Masquerading as Infra-His Wenckebach Due to Intra-atrial Conduction Delay–In Reply
Authors: Tai H. Pham, Ezra Amsterdam, Matthew S. Glassy
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Communication About Treatment Options and Shared Decision Making in the Intensive Care Unit
Authors: Terri R. Fried
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations
Authors: Jamie L. Everman, Satria Sajuthi, Benjamin Saef, Cydney Rios, Ari M. Stoner, Mari Numata, Donglei Hu, Celeste Eng, Sam Oh, Jose Rodriguez-Santana, Eszter K. Vladar, Dennis R. Voelker, Esteban G. Burchard, Max A. Seibold
Journal: Journal of Allergy and Clinical Immunology (2019)
Giant Cell Tumor of Tendon Sheath Revealed on 68Ga-DOTA-TATE PET/CT in a Patient With Suspicious Tumor-Induced Osteomalacia
Authors: Chaoyi Jia, Fuqiang Shao, Ming Yang, Chunxia Qin, Xiaoli Lan
Journal: Clinical Nuclear Medicine (2019)

Giant cell tumor of tendon sheath (GCTTS) is benign mesenchymal neoplasm, and it rarely induces hypophosphatemia. We report a 49-year-old woman with suspicious tumor-induced osteomalacia underwent Ga-DOTA-TATE PET/CT to identify potential causative tumor, which showed a hypermetabolic soft tissue nodule in the right foot. Pathology confirmed it as GCTTS following surgical resection. The patient's symptoms improved rapidly, and the serum phosphate normalized after surgery, which supports the diagnosis of tumor-induced osteomalacia. Our case showed GCTTS can be rich of somatostatin receptor and cause osteomalacia.
Recurrent Involuntary Contractions of the Face, Arm, and Leg in an Elderly Man
Authors: David Dongkyung Kim, Adrian Budhram, Seyed Mirsattari
Journal: JAMA Neurology (2019)

A man in his 60s presents to an epilepsy monitoring unit with transient episodes of expressive speech difficulties, paroxysmal dizziness, and involuntary nonsuppressible jerks of the right arm that begin without warning. What is your diagnosis?
Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma
Authors: Xiao-Peng Tian, Wei-Juan Huang, Hui-Qiang Huang, Yan-Hui Liu, Liang Wang, Xi Zhang, Tong-Yu Lin, Hui-Lan Rao, Mei Li, Fang Liu, Fen Zhang, Li-Ye Zhong, Li Liang, Xiao-Liang Lan, Juan Li, Bing Liao, Zhi-Hua Li, Qiong-Lan Tang, Qiong Liang, Chun-Kui Shao, Qiong-Li Zhai, Run-Fen Cheng, Qi Sun, Kun Ru, Xia Gu, Xi-Na Lin, Kun Yi, Yue-Rong Shuang, Xiao-Dong Chen, Wei Dong, Wei Sang, Cai Sun, Hui Liu, Zhi-Gang Zhu, Jun Rao, Qiao-Nan Guo, Ying Zhou, Xiang-Ling Meng, Yong Zhu, Chang-Lu Hu, Yi-Rong Jiang, Ying Zhang, Hong-Yi Gao, Wen-Jun He, Zhong-Jun Xia, Cheng-Lei Wu, Mei-Yin Zhang, Hui-Yun Wang, Dan Xie, Qing-Qing Cai
Journal: Leukemia (2019)
Abstract 11711: Heart Failure Following the Norwood Procedure
Authors: William T Mahle, Chenwei Hu, Felicia Trachtenberg, JonDavid Menteer, Steve Kindel, Anne I Dipchand, Marc E Richmond, Kevin Daly, Heather Henderson, Kimberly Lin, Michael McCulloch, Ashwin Lal, Kurt Schumacher, Jeffrey Jacobs, Andrew M Atz, Chet Villa, Kristin M Burns, Jane W Newburger
Journal: Circulation (2017)

Introduction: Some young children with hypoplastic left heart syndrome (HLHS) and its variants develop heart failure (HF) following the Norwood procedure (NP). We report the incidence of and risk f...
Novel 3-D helix-flexible nerve guide conduits repair nerve defects
Authors: Qi Quan, Haoye Meng, Biao Chang, Lei Hong, Rui Li, GuangBo Liu, XiaoQing Cheng, He Tang, Ping Liu, Yi Sun, Jiang Peng, Qing Zhao, Yu Wang, ShiBi Lu
Journal: Biomaterials (2019)
Effectiveness of a brief group psychological intervention for women in a post-conflict setting in Pakistan: a single-blind, cluster, randomised controlled trial
Authors: Atif Rahman, Muhammad Naseem Khan, Syed Usman Hamdani, Anna Chiumento, Parveen Akhtar, Huma Nazir, Anum Nisar, Aqsa Masood, Iftikhar Ud Din, Nasir Ali Khan, Richard A Bryant, Katie S Dawson, Marit Sijbrandij, Duolao Wang, Mark van Ommeren
Journal: The Lancet (2019)
CNTO 860, a humanized anti-tissue factor monoclonal antibody, significantly improves tumor response to paclitaxel in a xenograft model of colon cancer
Authors: Richard S. Tawadros, Marian T. Nakada, G. Mark Anderson
Journal: Cancer Research (2006)

2432  Combination therapy is a standard treatment modality for several metastatic cancers including breast, lung and colon and often provides greater efficacy and potentially reduces drug toxicity. There is increasing evidence of clinical benefits from combining biologics with traditional chemotherapeutics. Targeting multiple cancer pathways may sensitize resistant cancer cells and minimize escape mechanisms. Tissue Factor (TF), a cell surface protein closely associated with disease progression in cancer patients, is an attractive target because of high levels of overexpression in a number of cancers including lung, colon, breast, and prostate cancers. Upregulation of inflammatory cytokines, and increased metastasis and angiogenesis have also been associated with TF expression. In several in vivo studies we demonstrated the ability of CNTO 860 to impact tumor growth and angiogenesis. In the current study we investigated potential benefits of combining CNTO 860 with paclitaxel in a colon cancer model. HT29 colon tumor fragments were implanted subcutaneously in nude mice and allowed to grow to 100 mm3. Mice were dosed with paclitaxel at of 30 mg/kg (MTD), every other day for five days (qODx5). Monotherapy with paclitaxel initially regressed all tumors, but all tumors recurred. In combination therapy, CNTO 860 was dosed throughout the study while paclitaxel was dosed as above. Combination therapy significantly reduced tumor burden (p
Catheter Ablation of Refractory Ventricular Fibrillation Storm After Myocardial Infarction
Authors: Yuki Komatsu, Mélèze Hocini, Akihiko Nogami, Philippe Maury, Petr Peichl, Yu-ki Iwasaki, Keita Masuda, Arnaud Denis, Quentin Voglimacci-Stephanopoli, Dan Wichterle, Mitsuharu Kawamura, Seiji Fukamizu, Yasuhiro Yokoyama, Yasushi Mukai, Tomoo Harada, Kentaro Yoshida, Ryobun Yasuoka, Masayuki Igawa, Koji Ohira, Wataru Shimizu, Kazutaka Aonuma, Josef Kautzner, Michel Haïssaguerre, Masaki Ieda
Journal: Circulation (2019)

Background: Ventricular fibrillation (VF) storm after myocardial infarction (MI) is a life-threatening condition that necessitates multiple defibrillations. Catheter ablation is a potentially effective treatment strategy for VF storm refractory to optimal medical treatment. However, its impact on patient survival has not been verified in a large population. Methods: We conducted a multicenter, retrospective observational study involving consecutive patients who underwent catheter ablation of post-MI refractory VF storm without preceding monomorphic ventricular tachycardia. The target of ablation was the Purkinje-related ventricular extrasystoles triggering VF. The primary outcome was in-hospital and long-term mortalities. Univariate logistic regression and Cox proportional-hazards analysis were used to evaluate clinical characteristics associated with in-hospital and long-term mortalities, respectively. Results: One hundred ten patients were enrolled (age, 65±11years; 92 men; left ventricular ejection fraction, 31±10%). VF storm occurred at the acute phase of MI (4.5±2.5 days after the onset of MI during the index hospitalization for MI) in 43 patients (39%), the subacute phase (&gt;1 week) in 48 (44%), and the remote phase (&gt;6 months) in 19 (17%). The focal triggers were found to originate from the scar border zone in 88 patients (80%). During in-hospital stay after ablation, VF storm subsided in 92 patients (84%). Overall, 30 (27%) in-hospital deaths occurred. The duration from the VF occurrence to the ablation procedure was associated with in-hospital mortality (odds ratio for each 1-day increase, 1.11 [95% CI, 1.03–1.20]; P =0.008). During follow-up after discharge from hospital, only 1 patient developed recurrent VF storm. However, 29 patients (36%) died, with a median survival time of 2.2 years (interquartile range, 1.2–5.5 years). Long-term mortality was associated with left ventricular ejection fraction &lt;30% (hazard ratio, 2.54 [95% CI, 1.21–5.32]; P =0.014), New York Heart Association class ≥III (hazard ratio, 2.68 [95% CI, 1.16–6.19]; P =0.021), a history of atrial fibrillation (hazard ratio, 3.89 [95% CI, 1.42–10.67]; P =0.008), and chronic kidney disease (hazard ratio, 2.74 [95% CI, 1.15–6.49]; P =0.023). Conclusions: In patients with MI presenting with focally triggered VF storm, catheter ablation of culprit triggers is lifesaving and appears to be associated with short- and long-term freedom from recurrent VF storm. Mortality over the long-term follow-up is associated with the severity of underlying cardiovascular disease and comorbidities in this specific patient population.
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
Authors: Li Che, Wenna Chi, Yu Qiao, Jie Zhang, Xinhua Song, Ye Liu, Lei Li, Jiaoyuan Jia, Maria G Pilo, Jingxiao Wang, Antonio Cigliano, Zhilong Ma, Wenhua Kuang, Zefang Tang, Zemin Zhang, Guanghou Shui, Silvia Ribback, Frank Dombrowski, Matthias Evert, Rosa Maria Pascale, Carla Cossu, Giovanni Mario Pes, Timothy F Osborne, Diego F Calvisi, Xin Chen, Ligong Chen
Journal: Gut (2019)

Objective Increased de novo fatty acid (FA) synthesis and cholesterol biosynthesis have been independently described in many tumour types, including hepatocellular carcinoma (HCC). Design We investigated the functional contribution of fatty acid synthase (Fasn)-mediated de novo FA synthesis in a murine HCC model induced by loss of Pten and overexpression of c-Met (sgPten/c-Met) using liver-specific Fasn knockout mice. Expression arrays and lipidomic analysis were performed to characterise the global gene expression and lipid profiles, respectively, of sgPten/c-Met HCC from wild-type and Fasn knockout mice. Human HCC cell lines were used for in vitro studies. Results Ablation of Fasn significantly delayed sgPten/c-Met-driven hepatocarcinogenesis in mice. However, eventually, HCC emerged in Fasn knockout mice. Comparative genomic and lipidomic analyses revealed the upregulation of genes involved in cholesterol biosynthesis, as well as decreased triglyceride levels and increased cholesterol esters, in HCC from these mice. Mechanistically, loss of Fasn promoted nuclear localisation and activation of sterol regulatory element binding protein 2 (Srebp2), which triggered cholesterogenesis. Blocking cholesterol synthesis via the dominant negative form of Srebp2 ( dnSrebp2 ) completely prevented sgPten/c-Met-driven hepatocarcinogenesis in Fasn knockout mice. Similarly, silencing of FASN resulted in increased SREBP2 activation and hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase ( HMGCR) expression in human HCC cell lines. Concomitant inhibition of FASN-mediated FA synthesis and HMGCR-driven cholesterol production was highly detrimental for HCC cell growth in culture. Conclusion Our study uncovers a novel functional crosstalk between aberrant lipogenesis and cholesterol biosynthesis pathways in hepatocarcinogenesis, whose concomitant inhibition might represent a therapeutic option for HCC.
Circulating Inflammation Proteins Associated With Lung Cancer in African Americans
Authors: Claire L. Meaney, Khadijah A. Mitchell, Adriana Zingone, Derek Brown, Elise Bowman, Yunkai Yu, Angela S. Wenzlaff, Christine Neslund-Dudas, Sharon R. Pine, Liang Cao, Ann G. Schwartz, Bríd M. Ryan
Journal: Journal of Thoracic Oncology (2019)
Atherosclerosis Treatment with Stimuli‐Responsive Nanoagents: Recent Advances and Future Perspectives
Authors: Ali Maruf, Yi Wang, Tieyin Yin, Junli Huang, Nan Wang, Colm Durkan, Youhua Tan, Wei Wu, Guixue Wang
Journal: Advanced Healthcare Materials (2019)

Abstract Atherosclerosis is the root of approximately one‐third of global mortalities. Nanotechnology exhibits splendid prospects to combat atherosclerosis at the molecular level by engineering smart nanoagents with versatile functionalizations. Significant advances in nanoengineering enable nanoagents to autonomously navigate in the bloodstream, escape from biological barriers, and assemble with their nanocohort at the targeted lesion. The assembly of nanoagents with endogenous and exogenous stimuli breaks down their shells, facilitates intracellular delivery, releases their cargo to kill the corrupt cells, and gives imaging reports. All these improvements pave the way toward personalized medicine for atherosclerosis. This review systematically summarizes the recent advances in stimuli‐responsive nanoagents for atherosclerosis management and its progress in clinical trials.
Dual lineage tracing shows that glomerular parietal epithelial cells can transdifferentiate toward the adult podocyte fate
Authors: Natalya V. Kaverina, Diana G. Eng, Benjamin S. Freedman, J. Nathan Kutz, Tyler J. Chozinski, Joshua C. Vaughan, Jeffrey H. Miner, Jeffrey W. Pippin, Stuart J. Shankland
Journal: Kidney International (2019)
Recent advances in obstetrics
Authors: D. Warner
Journal: BMJ (1996)

Tuberculosis Research Unit for the streptomycin trial,4 which subsequently (from 1948) served as a model for randomisation in many later randomised controlled trials?Or is it because the results of the patulin trial were negative and those of the streptomycin trial made medical history?I have previously quoted Bradford Hill's re- collection that his statistical, and my medical, experiences in this field converged when we pre- pared for the streptomycin project.56The patulin trial certainly influenced my thinking.Yet, so far as I am aware, the literature on the modem clinical trial contains no recognition of this trial, despite its many deserving features.Should not this omission be rectified?
Engaging Mental Health Professionals in Addressing Pain
Authors: Sara N. Edmond, Alicia A. Heapy, Robert D. Kerns
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema
Authors: Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum
Journal: Clinical Nuclear Medicine (2019)

Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of prostate cancer cells, which has led to the development of radiolabeled small-molecule inhibitors of PSMA for molecular imaging and targeted radioligand therapy. Lu-labeled PSMA, with therapeutic β-emission and concomitant γ radiation, permits posttherapy imaging for the assessment of biodistribution and uptake in tumors and normal organs, as well as dosimetry. We report a patient with prostate cancer and metastatic lymph nodes-related lower extremity lymphedema, who presented with dermal backflow and soft-tissue uptake in the lower extremity on posttherapeutic whole body scan after intravenous Lu-PSMA treatment.